Technical Analysis for GTBP - GT Biopharma, Inc.

Grade Last Price % Change Price Change
C 9.38 -4.67% -0.46
GTBP closed up 7.78 percent on Friday, April 16, 2021, on 54 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Up
Historical GTBP trend table...

Date Alert Name Type % Chg
Inside Day Range Contraction -4.67%
Wide Bands Range Expansion -4.67%
Wide Bands Range Expansion 2.74%
New Uptrend Bullish -2.60%
Calm After Storm Range Contraction -2.60%
NR7 Range Contraction -2.60%
Upper Bollinger Band Walk Strength -2.60%
Multiple of Ten Bearish Other -2.60%
Inside Day Range Contraction -2.60%
Wide Bands Range Expansion -2.60%
Older End-of-Day Signals for GTBP ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 5% less than a minute ago
Down 3% 11 minutes ago
Down 2 % 11 minutes ago
Fell Below 10 DMA 11 minutes ago
10 DMA Support 27 minutes ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

GT Biopharma, Inc. Description

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology products based on its proprietary technology platforms. The company develops immuno-oncology product candidates, including GTB-1550, a bispecific scFv recombinant fusion protein-drug conjugate that targets cancer cells expressing the CD19 receptor or CD22 receptor, or both receptors, which is in Phase 2 clinical trial; GTB-3550, a single-chain, tri-specific scFv recombinant fusion protein conjugate that is in Phase 1 clinical trial; GTB-C3550, a next-generation follow-on to its lead candidates TriKE, GTB-3550, and GTB-C3550, which contains a modified CD16 moiety; and GTB-1615, a single-chain fusion protein for the treatment of solid tumors. Its central nervous system portfolio consists of GTP-004 for the treatment of myasthenia gravis, PainBrake to treat chronic neuropathic pain, and GTP-011 for the treatment of motion sickness. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a novel 161533 TriKE fusion protein for cancer therapies; and a collaboration agreement with Cytovance Biologics to provide development services for a TriKE therapeutic for the treatment of coronavirus infection. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is headquartered in Westlake Village, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Solid Tumors Cancer Therapies Lectins Myasthenia Gravis Coronavirus Infection Treatment Of Myasthenia Gravis

Is GTBP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 10.87
52 Week Low 3.91
Average Volume 702,562
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 8.11
10-Day Moving Average 9.53
Average True Range 1.01
ADX 23.98
+DI 23.61
-DI 17.09
Chandelier Exit (Long, 3 ATRs ) 7.83
Chandelier Exit (Short, 3 ATRs ) 8.90
Upper Bollinger Band 11.10
Lower Bollinger Band 5.13
Percent B (%b) 0.79
BandWidth 73.67
MACD Line 1.04
MACD Signal Line 0.95
MACD Histogram 0.0926
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.27
Resistance 3 (R3) 11.12 10.51 11.03
Resistance 2 (R2) 10.51 10.14 10.58 10.95
Resistance 1 (R1) 10.17 9.92 10.34 10.32 10.87
Pivot Point 9.56 9.56 9.64 9.63 9.56
Support 1 (S1) 9.22 9.19 9.39 9.37 8.81
Support 2 (S2) 8.61 8.97 8.68 8.73
Support 3 (S3) 8.27 8.61 8.65
Support 4 (S4) 8.42